Go to content
UR Home

Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the study alliance leukemia

Müller-Tidow, C ; Tschanter, P ; Röllig, C ; Thiede, C ; Koschmieder, A ; Stelljes, M ; Koschmieder, S ; Dugas, M ; Gerss, J ; Butterfaß-Bahloul, T ; Wagner, R ; Eveslage, M ; Thiem, U ; Krause, S W ; Kaiser, U ; Kunzmann, V ; Steffen, B ; Noppeney, R ; Herr, W ; Baldus, C D ; Schmitz, N ; Götze, K ; Reichle, A ; Kaufmann, M ; Neubauer, A ; Schäfer-Eckart, K ; Hänel, M ; Peceny, R ; Frickhofen, N ; Kiehl, M ; Giagounidis, A ; Görner, M ; Repp, R ; Link, H ; Kiani, A ; Naumann, R ; Brümmendorf, T H ; Serve, H ; Ehninger, G ; Berdel, W E ; Krug, U



Abstract

DNA methylation changes are a constant feature of acute myeloid leukemia. Hypomethylating drugs such as azacitidine are active in acute myeloid leukemia (AML) as monotherapy. Azacitidine monotherapy is not curative. The AML-AZA trial tested the hypothesis that DNA methyltransferase inhibitors such as azacitidine can improve chemotherapy outcome in AML. This randomized, controlled trial compared ...

plus


Owner only: item control page
  1. Homepage UR

University Library

Publication Server

Contact:

Publishing: oa@ur.de

Dissertations: dissertationen@ur.de

Research data: daten@ur.de

Contact persons